Moleculin Reports Independent Assessment Finds No Cardiotoxicity in 90 Subjects Treated with Annamycin

Moleculin Biotech reported that an independent assessment of 90 subjects treated with Annamycin, a next-generation anthracycline, found no evidence of cardiotoxicity. The data from five clinical trials treating acute myeloid leukemia and soft tissue sarcoma was reviewed by an expert affiliated with a leading cancer research institute. The assessment found no evidence of cardiotoxicity, even in subjects who received more than the FDA's lifetime maximum cumulative anthracycline exposure. This bolsters Moleculin's confidence in Annamycin's safety and potential efficacy in treating multiple oncology indications.